Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KA-301 amnion-derived mesenchymal stem cells for Duchenne muscular dystrophy
jRCT2033230295Recruiting
- Sponsor
- Kaneka
- Start
- Sep 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of KA-301 in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Kaneka. Primary endpoint: Safety endpoints. Started Sep 2023; status: recruiting.
02
Drugs
KA-301
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2033230295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230295.